Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)

ARTO (ClinicalTrials.gov identifier: NCT03449719) is a multicenter, phase II randomized clinical trial testing the benefit of adding stereotactic body radiation therapy (SBRT) to abiraterone acetate and prednisone (AAP) in patients with oligometastatic castrate-resistant prostate cancer (CRPC). All...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2023-12, Vol.41 (36), p.5561-5568
Hauptverfasser:	Francolini, Giulio, Gaetano Allegra, Andrea, Detti, Beatrice, Di Cataldo, Vanessa, Caini, Saverio, Bruni, Alessio, Ingrosso, Gianluca, D'Angelillo, Rolando Maria, Alitto, Anna Rita, Augugliaro, Matteo, Triggiani, Luca, Parisi, Silvana, Facchini, Gaetano, Banini, Marco, Simontacchi, Gabriele, Desideri, Isacco, Meattini, Icro, Valicenti, Richard K, Livi, Lorenzo
Format:	Artikel
Sprache:	eng
Schlagworte:	Abiraterone Acetate - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Humans Male Prednisone - therapeutic use Prostate-Specific Antigen Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - radiotherapy Radiosurgery - adverse effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!